Fluorescein 0.25% / Proparacaine 0.5% · ophthalmic solution
Diagnostic Dye, Local Anesthetic
Approved uses
Ophthalmic procedures requiring a disclosing agent with topical anesthesia
1 to 2 drops in each eye as single instillations before foreign body or suture removal and before tonometry; for deep ophthalmic anesthesia, 1 drop in each eye every 5 to 10 minutes for 5 to 7 doses
Its proparacaine component numbs the cornea within 1 minute, with sensitivity back by 45 minutes.
Contraindications
Known hypersensitivity to any component of this product.
Fluorescein sodium 0.25% (2.5 mg/mL) and proparacaine hydrochloride 0.5% (5 mg/mL), 5 mL glass bottle
Combination of a disclosing dye with a rapidly acting anesthetic of short duration. Fluorescein 0.25% is excluded by intact corneal epithelium and pools where the barrier is broken, fluorescing yellow-green under cobalt blue light, while proparacaine 0.5%, an ester anesthetic, blocks sodium channel conduction in corneal and conjunctival sensory nerve endings.
Warnings & Precautions
- Permanent corneal opacification: Prolonged use of a topical ocular anesthetic is not recommended and may produce permanent corneal opacification with visual loss.
- Delayed wound healing: The long-term toxicity is unknown, and prolonged use may possibly delay wound healing. In primary human corneal fibroblasts and in New Zealand white rabbits, proparacaine 0.5% and 0.05% applied twice daily for 3 days impeded corneal wound healing in a time-dependent manner, adjunct polymyxin B sulfate and trimethoprim had additive effects, and diluted proparacaine without antibiotics had minimal negative effects.
- Systemic toxicity: Although exceedingly rare with ophthalmic application of local anesthetics, systemic toxicity manifested by central nervous system stimulation followed by depression may occur.
- Cautious use: Use this product cautiously and sparingly in patients with known allergies, cardiac disease, or hyperthyroidism.
- Corneal protection during anesthesia: Protect the eye from irritating chemicals, foreign bodies, and rubbing until sensation returns, and keep the patient from touching the eye.
- Tonometer rinsing: Tonometers soaked in sterilizing or detergent solutions should be thoroughly rinsed with sterile distilled water before use.
- Dropper contamination: Do not touch the sterile dropper tip to any surface, and replace the container closure immediately after use.
- Contamination of combination solutions: Of four commercially available fluorescein-anesthetic solutions inoculated with Pseudomonas or Staphylococcus species, no organisms could be cultured from Fluress one minute after inoculation of the solution or five minutes after the dropper tip, but organisms were cultured from the others for at least one hour. Reused unpreserved single-application fluorescein 0.25% with proxymethacaine 0.5% Minims grew lid and conjunctival flora in 7 of 41 samples (17%).
- Storage: Refrigerate at 2 to 8 degrees C, with up to 1 month at room temperature.
Common Side Effects
Occasional temporary stinging, burning, and conjunctival redness have been reported after use of ocular anesthetics, as well as a rare, severe, immediate-type, apparent hyper-allergic corneal reaction with acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and sometimes iritis with descemetitis. Allergic contact dermatitis with drying and fissuring of the fingertips has been reported.
Pregnancy: The label has no pregnancy section and does not address use in pregnancy.
Lactation: The label has no nursing mothers section and does not address use during breastfeeding.
The label has no pediatric use section and does not address use in children.